Integrated Biopharma Performance
| INBPDelisted Stock | USD 0.33 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.36, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Integrated Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Integrated Biopharma is expected to be smaller as well. Integrated Biopharma right now retains a risk of 0.0%. Please check out Integrated Biopharma treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Integrated Biopharma will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Integrated Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental drivers, Integrated Biopharma is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 210 K | |
| Total Cashflows From Investing Activities | -465 K |
Integrated |
Integrated Biopharma Relative Risk vs. Return Landscape
If you would invest 33.00 in Integrated Biopharma on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Integrated Biopharma or generate 0.0% return on investment over 90 days. Integrated Biopharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Integrated, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Integrated Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Integrated Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Integrated Biopharma, and traders can use it to determine the average amount a Integrated Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| INBP |
Based on monthly moving average Integrated Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Integrated Biopharma by adding Integrated Biopharma to a well-diversified portfolio.
Integrated Biopharma Fundamentals Growth
Integrated OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Integrated Biopharma, and Integrated Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Integrated OTC Stock performance.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0336 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 12.05 M | ||||
| Shares Outstanding | 29.95 M | ||||
| Price To Earning | 2.52 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 0.21 X | ||||
| Revenue | 56.25 M | ||||
| EBITDA | 3.54 M | ||||
| Cash And Equivalents | 343 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 53 K | ||||
| Debt To Equity | 0.11 % | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | 4.09 M | ||||
| Earnings Per Share | 0.11 X | ||||
| Total Asset | 25.25 M | ||||
| Retained Earnings | (59.89 M) | ||||
| Current Asset | 12.7 M | ||||
| Current Liabilities | 11.79 M | ||||
About Integrated Biopharma Performance
Assessing Integrated Biopharma's fundamental ratios provides investors with valuable insights into Integrated Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Integrated Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 147 people.Things to note about Integrated Biopharma performance evaluation
Checking the ongoing alerts about Integrated Biopharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Integrated Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Integrated Biopharma is not yet fully synchronised with the market data | |
| Integrated Biopharma has some characteristics of a very speculative penny stock | |
| Integrated Biopharma has a very high chance of going through financial distress in the upcoming years | |
| About 69.0% of the company shares are held by company insiders |
- Analyzing Integrated Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Integrated Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Integrated Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Integrated Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Integrated Biopharma's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Integrated Biopharma's otc stock. These opinions can provide insight into Integrated Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Global Correlations Find global opportunities by holding instruments from different markets |